Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 12;135(11):862-865.
doi: 10.1182/blood.2019002920.

Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas

S A Srour  1 , H Singh  2 , J McCarty  1 , E de Groot  3 , H Huls  2 , G Rondon  1 , M Qazilbash  1 , S Ciurea  1 , G Bardelli  3 , J Buck  3 , A Alousi  1 , Y Nieto  1 , K Rezvani  1 , D Marin  1 , U Popat  1 , C Hosing  1 , E J Shpall  1 , W G Wierda  4 , H Kantarjian  4 , R E Champlin  1 , L J Cooper  3 , P Kebriaei  1
Affiliations

Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas

S A Srour et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: E.d.G. is Executive Vice President and General Manager of Cell Therapy at Ziopharm Oncology, Inc.; and is a visiting scientist at MD Anderson Cancer Center. E.d.G. has financial relationships as follows: salary (Ziopharm Oncology) and ownership interest (Ziopharm Oncology). M.Q. has received research funding from Janssen, Bioline, and Angiocrine; and has been a consultant for Autolus Limited and Bioclinica Inc. G.B. and J.B. have financial relationships as follows: salary (Ziopharm Oncology) and ownership interest (Ziopharm Oncology). E.J.S. has served on advisory boards for Adaptimmune, CART Coop, Novartis, Axio, and Zelluna. L.J.C. is listed as inventors of certain intellectual property described in this article; is the CEO of Ziopharm Oncology, Inc.; and is a visiting scientist at MD Anderson Cancer Center. L.J.C. has financial relationships as follows: salary (Ziopharm Oncology, MD Anderson Cancer Center [until May 2015]), royalty (City of Hope, Immatics), contracted research (Ziopharm Oncology, Inc.), and ownership interest (Targazyme, Ziopharm Oncology, Immatics, Kiadis, and CellChorus). P.K. has served on advisory boards for Kite and Pfizer; received research support from Amgen and Ziopharm; and has been a consultant for Jazz. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Patient outcomes and persistence of CAR T cells after therapy. (A) Progression-free survival (PFS) and overall survival (OS) of study patients. (B) Persistence of genetically modified T cells postinfusion was assessed by droplet digital PCR (ddPCR) and by flow cytometry as previously described. ddPCR was used to evaluate integrated CAR transgene copy number per microgram of genomic DNA (gDNA). Insets (bar graphs) show CAR copy number (mean ± standard deviation [SD], log-axis) at the latest time point. CAR+ Jurkat Clone 12 (stably expressing CD19-specific CAR [P]) was used as positive control, and Water (W) was used as negative control alongside patient sample (S). Using flow cytometry, total viable cells were gated to reveal CD3+CAR+ T cells and CD19+CD20+ B cells. Ex vivo expanded, genetically modified CD19-specific CARpos T cells were used as positive controls, and CARneg normal donor peripheral blood mononuclear cells or ex vivo expanded mock electroporated cells were used as negative controls.
See this image and copyright information in PMC

References

    1. Philip T, Guglielmi C, Hagenbeek A, et al. . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540-1545. - PubMed
    1. Cohen JB. Novel therapies for relapsed/refractory aggressive lymphomas. Hematology (Am Soc Hematol Educ Program). 2018;2018(1):75-82. - PMC - PubMed
    1. Srour SA, Li S, Popat UR, et al. . A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-Hodgkin lymphomas: long term results. Br J Haematol. 2017;178(4):561-570. - PMC - PubMed
    1. Gisselbrecht C, Glass B, Mounier N, et al. . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190. - PMC - PubMed
    1. Crump M, Neelapu SS, Farooq U, et al. . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. - PMC - PubMed

Publication types